

the Reply to the Written Opinion, mailed March 13, 2000. The IPER stated that several amendments were not accepted, and these are discussed below.

Applicant also respectfully requests the entry of the following amendments:

In the Specification:

At page 5, line 8, please delete "its U.S. designation".

At page 5, line 9, please replace "XX/XXX,XXX" with --09/____,____, "Restin and Methods of Use Thereof", by Vikas P. Sukhatme, filed June __, 2000--.

At page 5, line 11, please delete "its U.S. designation".

At page 5, line 11, please replace "XX/XXX,XXX" with --09/____,____, "Anti-Angiogenic Peptides and Methods of Use Thereof", by Vikas P. Sukhatme, filed June __, 2000--.

At page 20, line 14, please delete "its U.S. designation".

At page 20, line 14, please replace "XX/XXX,XXX" with --09/____,____, "Anti-Angiogenic Peptides and Methods of Use Thereof", by Vikas P. Sukhatme, filed June __, 2000--.

At page 20, line 30, please delete "its U.S. designation".

At page 20, line 30, please replace "XX/XXX,XXX" with --09/____,____, "Restin and Methods of Use Thereof", by Vikas P. Sukhatme, filed June __, 2000--.

At page 30, line 4, please delete "μ".

At page 46, lines 22-23, please replace "U.S. patent application, U.S.S.N.: XX/XXX,XXX" with --PCT/US98/26057--.

At page 46, line 23, please replace "Anti-Angiogenic Peptides and Methods of Use Thereof" with --Mutants of Endostatin, 'EM 1' Having Anti-Angiogenic Activity and Methods of Use Thereof--.

At page 47, line 2, please delete "its U.S. designation".

At page 47, line 3, please replace "XX/XXX,XXX" with --09/____,____, "Anti-Angiogenic Peptides and Methods of Use Thereof", by Vikas P. Sukhatme, filed June __, 2000--.

At page 49, line 10, please delete "its U.S. designation".

At page 49, line 11, please replace "XX/XXX,XXX" with --09/____,____, "Anti-Angiogenic Peptides and Methods of Use Thereof", by Vikas P. Sukhatme, filed June __, 2000--.